Re: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017;20:692-702

Journal article

Peer reviewed

Jayeshkumar Patel, Xiaohui Zhao, Drishti Shah, Khalid Alhussain and Khalid Kamal

Journal of medical economics, Vol.20(11), pp.1121-1122

02/11/2017

PMID: 28745535

Abstract

Cost-Benefit Analysis

Genotype

Hepatitis C, Chronic

Humans

Imidazoles

Sofosbuvir

United States

1 Record Views

Title: Re: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017;20:692-702
Creators - without role: Jayeshkumar Patel - West Virginia University
Xiaohui Zhao - West Virginia University
Drishti Shah - West Virginia University
Khalid Alhussain - West Virginia University
Khalid Kamal - Duquesne University
Publication Details: Journal of medical economics, Vol.20(11), pp.1121-1122
Identifiers: 9919815108331
Academic Unit: King Faisal University
Language: English
Resource Type: Journal article